AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

Breadth: Four Businesses in 160 CountriesNarrow moat

Abbott Laboratories (ABT) — moat facet

Abbott's breadth across four businesses and 160 countries has carried a 54-year dividend record, but it averages strong businesses with weak ones.

Abbott's fourth moat is the one that holds the other three together: breadth. It sells devices, diagnostics, nutrition and branded generics, and its people "serve people in more than 160 countries"1. Abbott says it "has no single customer that, if the customer was lost, would have a material adverse effect on Abbott"2.

Abbott sales growth by segment, 2025 (%)+12.6Medical Devices+6.6Established Pharma+0.5Nutrition-4.3DiagnosticsAbbott Form 10-K FY2025, segment note; Moat Explorer calculation
Four segments, four different directions.

Breadth protects against the failure of any one part. When COVID testing collapsed, devices grew. When Sturgis shut, the rest of the company paid for the recall. The dividend has risen for 54 consecutive years3, through the AbbVie separation and the pandemic.

The breadth was curated. Abbott spun off AbbVie, its research-based pharmaceuticals business4, which this app covers on its own pages. It sold the developed-markets generics to Mylan on 27 February 20155 and Abbott Medical Optics to Johnson & Johnson for $4.325 billion in 20176. It bought St. Jude Medical for about $23.6 billion and Alere for about $4.5 billion in the same year7, and Exact Sciences for about $20.6 billion in 20268.

Breadth also has a cost. Diversification averages strong businesses with weak ones, and in 2025 Medical Devices sales grew 12.6% while Diagnostics fell 4.3% and Nutrition rose 0.5%9. Return on invested capital was 11.3% in 202510, above an 8% hurdle but well below the 16.5% of 2021.

The breadth is physical as well as commercial. Long-lived assets, mostly property and equipment, were $22.2 billion at the end of 2025 against $18.5 billion a year earlier11, and Abbott's 89 manufacturing sites are spread across all four segments12. The company that sells in 160 countries also makes in many of them.

The cash returned shows breadth at work. Abbott paid dividends of $3,556 million in 2023, $3,836 million in 2024 and $4,116 million in 2025, and spent $1,227 million, $1,295 million and $893 million on share purchases13. Those payments came from a portfolio in which at least one segment was always declining.

The rating is narrow. The breadth is real and makes Abbott durable; it does not make it a high-return company. If the dividend streak is intact in 2030 but return on capital has slipped below 9%, breadth will have bought safety rather than value.

Moat trajectory: Holding steady

No material customer; dividend raised 54 years; ROIC 11.3% in 2025.

The number that tests this moat
Reported
Established Pharmaceuticals sales growth, latest quarter
+8.4% reported, +8.7% comparable (Q2 2026: $1,499M)

The smallest segment's growth as a check on breadth; a slowdown below 5% would leave devices carrying even more.

Source: Abbott Q2 2026 earnings release ↗
Aspects of the moat
DIG DEEPER 01
Branded Generics Where the Brand Is the Guarantee
Abbott's branded generics earn on the trust its name carries in emerging-market pharmacies, and the segment margin rose from 17.7% to 23.3% in ten…
DIG DEEPER 02
Thirty-Seven Percent in Emerging Markets
Abbott makes 61% of its sales outside the US and 37% in emerging markets, a network built over decades that newcomers must build from scratch.
DIG DEEPER 03
Eighty-Nine Factories
Abbott makes its sensors, devices, reagents and formula in 89 plants of its own, and sells about 1.6 times DexCom's revenue in glucose monitors alone.
DIG DEEPER 04
Fifty-Four Years of Dividend Increases
Abbott has raised its dividend for 54 years and paid 55.7% of 2025 free cash flow as dividends; the record shows how durable four businesses together…
⚠ Threats to the moat
⚠ THREAT 01
Currency: Sales Up, Earnings Down
Foreign exchange raised Abbott's 2025 sales and lowered its operating earnings, the mismatch of a company that sells 61% abroad.
⚠ THREAT 02
Diversification That Averages Down
Abbott's return on invested capital fell from 16.5% in 2021 to 11.3% in 2025, and Exact Sciences adds $23 billion of goodwill and intangibles.
References
  1. ReportedIt sells devices, diagnostics, nutrition and branded generics, and its people "serve people in more than 160 countries".
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Diagnostics sales by business, Cancer Diagnostics and Cologuard. — Q2 2026 · publ. 16 July 2026 · source ↗
  2. ReportedAbbott says it "has no single customer that, if the customer was lost, would have a material adverse effect on Abbott".
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - Item 1 business and the segment note: the four segments, sales and operating earnings, employees, manufacturing sites, customers and geography. — FY2025 · publ. 20 February 2026 · source ↗
  3. ReportedThe dividend has risen for 54 consecutive years, through the AbbVie separation and the pandemic.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - total sales, income statement, specified items, tax rate, guidance and the dividend. — Q2 2026 · publ. 16 July 2026 · source ↗
  4. ReportedAbbott spun off AbbVie, its research-based pharmaceuticals business, which this app covers on its own pages.
    Abbott Laboratories Form 10-K for 2015 - the AbbVie separation, the sale of the developed-markets branded generics business to Mylan on 27 February 2015 for 110 million Mylan N.V. shares, the CFR Pharmaceuticals purchase, operating earnings and the balance sheet at 31 December 2015. — FY2015 · publ. February 2016 · source ↗
  5. ReportedIt sold the developed-markets generics to Mylan on 27 February 2015 and Abbott Medical Optics to Johnson & Johnson for $4.325 billion in 2017.
    Abbott Laboratories Form 10-K for 2015 - the AbbVie separation, the sale of the developed-markets branded generics business to Mylan on 27 February 2015 for 110 million Mylan N.V. shares, the CFR Pharmaceuticals purchase, operating earnings and the balance sheet at 31 December 2015. — FY2015 · publ. February 2016 · source ↗
  6. ReportedIt sold the developed-markets generics to Mylan on 27 February 2015 and Abbott Medical Optics to Johnson & Johnson for $4.325 billion in 2017.
    Abbott Laboratories Form 10-K for 2017 - the St. Jude Medical acquisition (closed 4 January 2017, about $23.6 billion), the Alere acquisition (3 October 2017, about $4.5 billion), the sale of Abbott Medical Optics to Johnson & Johnson for $4.325 billion, net sales and earnings for 2015-2017, the 84.2% 2017 tax rate and the balance sheet at 31 December 2017. — FY2017 · publ. February 2018 · source ↗
  7. ReportedJude Medical for about $23.6 billion and Alere for about $4.5 billion in the same year, and Exact Sciences for about $20.6 billion in 2026.
    Abbott Laboratories Form 10-K for 2017 - the St. Jude Medical acquisition (closed 4 January 2017, about $23.6 billion), the Alere acquisition (3 October 2017, about $4.5 billion), the sale of Abbott Medical Optics to Johnson & Johnson for $4.325 billion, net sales and earnings for 2015-2017, the 84.2% 2017 tax rate and the balance sheet at 31 December 2017. — FY2017 · publ. February 2018 · source ↗
  8. ReportedJude Medical for about $23.6 billion and Alere for about $4.5 billion in the same year, and Exact Sciences for about $20.6 billion in 2026.
    Abbott Laboratories Form 10-Q for the quarter ended 30 June 2026 - segment sales and operating earnings, the Exact Sciences acquisition and purchase-price allocation, the $20.0 billion of notes, remaining performance obligations, goodwill by segment, expected amortization, legal reserves and the NEC litigation, and the balance sheet at 30 June 2026 - the Exact Sciences acquisition, purchase-price allocation, goodwill by segment and expected amortization. — Q2 2026 · publ. 28 July 2026 · source ↗
  9. Moat Explorer calcDiversification averages strong businesses with weak ones, and in 2025 Medical Devices sales grew 12.6% while Diagnostics fell 4.3% and Nutrition rose 0.5%.
    Moat Explorer calculation from Abbott Laboratories reported figures ($ millions unless stated; calendar years). Medical Devices: share of total reportable segment operating earnings 3,011 / 6,916 = 43.5% (2017), 4,533 / 13,422 = 33.8% (2021), 7,212 / 11,800 = 61.1% (2025); first half 2026 3,862 / 6,122 = 63.1%. Share of segment sales 21,387 / 44,311 = 48.3% (2025); first half 2026 11,392 / 23,750 = 48.0%. Segment margin 3,011 / 10,325 = 29.2% (2017), 3,038 / 11,787 = 25.8% (2020), 4,533 / 14,485 = 31.3% (2021), 7,212 / 21,387 = 33.7% (2025); Q2 2026 1,969 / 5,853 = 33.6%, Q2 2025 1,796 / 5,369 = 33.5%. Sales growth 2017-2025 (21,387 / 10,325)^(1/8) - 1 = 9.5% a year; operating earnings 2025 7,212 / 6,153 - 1 = +17.2%; sales 2025 21,387 / 18,986 - 1 = +12.6%. Diabetes Care 7,998 / 1,414 = 5.66 times (2017 to 2025); share of Medical Devices 1,414 / 10,325 = 13.7% (2017), 2,524 / 12,239 = 20.6% (2019), 4,328 / 14,485 = 29.9% (2021), 5,761 / 16,887 = 34.1% (2023), 7,998 / 21,387 = 37.4% (2025); share of company 7,998 / 44,328 = 18.0%; CGM share of Diabetes Care 7.6bn / 7.998bn = 95%. CGM growth 2019-2025 (7.6 / 1.842)^(1/6) - 1 = 26.6% a year. Abbott CGM sales over DexCom revenue 7,600 / 4,662.0 = 1.63 times. DexCom distributor share 3,959.0 / 4,662.0 = 84.9%. Product lines 2017 to 2025: Electrophysiology 2,764 / 1,353 = 2.04 times; Structural Heart 2,523 / 1,083 = 2.33 times; Heart Failure 1,448 / 643 = 2.25 times; Rhythm Management 2,649 / 2,132 - 1 = +24.2%; Neuromodulation 1,010 / 808 - 1 = +25.0%; Vascular 2,995 / 2,892 - 1 = +3.6%. Rhythm Management, Heart Failure, Vascular and Neuromodulation together 2,649 + 1,448 + 2,995 + 1,010 = 8,102 (2025) against 2,390 + 1,279 + 2,837 + 962 = 7,468 (2024), +8.5%. Diagnostics: margin 1,912 / 7,713 = 24.8% (2019), 6,237 / 15,526 = 40.2% (2021), 6,640 / 16,469 = 40.3% (2022), 2,433 / 9,988 = 24.4% (2023), 1,740 / 8,937 = 19.5% (2025); Q2 2026 499 / 3,092 = 16.1%, Q2 2025 372 / 2,173 = 17.1%. Share of segment operating earnings 6,640 / 12,831 = 51.7% (2022), 1,740 / 11,800 = 14.7% (2025). Sales 2025 8,937 / 9,341 - 1 = -4.3%. COVID testing share of Diagnostics sales 2022 8.4bn / 16.469bn = 51%, about half. Core Laboratory 5,360 / 4,063 - 1 = +31.9%. Rapid Diagnostics 2,454 / 10,061 - 1 = -75.6% (2022 to 2025). Point of Care 606 / 550 - 1 = +10.2%. Molecular 2020 peak 1,438 / 463 = 3.11 times 2017. Cancer Diagnostics share of Diagnostics Q2 2026 919 / 3,092 = 29.7%. Exact Sciences US share of 2025 sales 3,145 / 3,247 = 96.9%; purchase price over 2025 sales 20.6bn / 3.247bn = 6.3 times. China net sales 1,907 / 2,253 - 1 = -15.4% (2023 to 2025); China share of company 2,253 / 40,109 = 5.6% (2023), 1,907 / 44,328 = 4.3% (2025). Nutrition: margin 1,741 / 6,975 = 25.0% (2015), 1,705 / 7,409 = 23.0% (2019), 1,763 / 8,294 = 21.3% (2021), 706 / 7,459 = 9.5% (2022), 1,333 / 8,154 = 16.3% (2023), 1,558 / 8,451 = 18.4% (2025); Q2 2026 368 / 2,144 = 17.2%, Q2 2025 418 / 2,212 = 18.9%. Q2 operating earnings 368 / 418 - 1 = -12.0%. Sales 2021 to 2025 8,451 / 8,294 - 1 = +1.9%. Share of company sales 6,925 / 27,390 = 25.3% (2017), 7,409 / 31,904 = 23.2% (2019), 8,294 / 43,075 = 19.3% (2021), 8,154 / 40,109 = 20.3% (2023), 8,451 / 44,328 = 19.1% (2025). US Pediatric 2022 1,562 / 2,192 - 1 = -28.7%. International Adult 3,029 / 1,782 - 1 = +70.0% (2017 to 2025); share of Nutrition 3,029 / 8,451 = 35.8%. International Pediatric 1,816 / 2,112 - 1 = -14.0%. Sturgis: recalled brands 479 / 1,200 - 1 = -60%; Nutrition operating earnings 706 / 1,763 - 1 = -60%. Established Pharmaceuticals: margin 658 / 3,720 = 17.7% (2015), 848 / 4,287 = 19.8% (2017), 904 / 4,486 = 20.2% (2019), 889 / 4,718 = 18.8% (2021), 1,206 / 5,066 = 23.8% (2023), 1,290 / 5,536 = 23.3% (2025); Q2 2026 382 / 1,499 = 25.5%. Sales 5,536 / 3,720 - 1 = +48.8% (2015 to 2025); (5,536 / 4,287)^(1/8) - 1 = 3.2% a year (2017 to 2025). Key Emerging Markets share 4,167 / 5,536 = 75.3%. Segment sales growth 2025: Medical Devices +12.6%, Established Pharmaceuticals 5,536 / 5,194 - 1 = +6.6%, Nutrition 8,451 / 8,413 - 1 = +0.5%, Diagnostics -4.3%; net sales 44,328 / 41,950 - 1 = +5.7%. US share of 2025 net sales 17,126 / 44,328 = 38.6%; international share Q2 2026 7,377 / 12,593 = 58.6%. Further: Structural Heart compensation payments 89 / 2,523 = 3.5% of 2025 line sales. Diabetes Care added 7,998 - 6,805 = 1,193 in 2025. One point of CGM growth on 7.6bn = about 76. Medical Devices share of segment assets 10,689 / (3,540 + 4,791 + 8,273 + 10,689 = 27,293) = 39.2%. Total debt over total assets 32,608 / 109,215 = 29.9% (30 June 2026), 12,929 / 86,713 = 14.9% (end 2025). Net debt over Abbott shareholders' investment 27,005 / 51,110 = 0.53. Market value 173.21 / 217.86 - 1 = -20.5% (end 2025 to 5 October 2026). Second pass: US Structural Heart first half 2026 449 / 1,175 = 38.2%. Rapid Diagnostics 2,454 / 4,376 = 56% of 2020. Diagnostics Q2 2026 operating earnings 499 / 372 - 1 = +34.1%. Nutrition sales (8,451 / 6,925)^(1/8) - 1 = 2.5% a year (2017 to 2025); 8,451 / 7,409 - 1 = +14.1% (2019 to 2025). US Adult Nutrition 1,448 / 1,254 - 1 = +15.5% (2017 to 2025). Adult nutrition 3,029 + 1,448 = 4,477; pediatric 2,158 + 1,816 = 3,974 (2025). Total segment operating earnings 11,800 / 13,422 - 1 = -12.1% (2021 to 2025); Medical Devices 7,212 / 4,533 - 1 = +59.1%. First half 2026 dividends over operating cash flow 2,200 / 3,803 = 57.9%. DexCom revenue 2023 3,095.6 + 526.7 = 3,622.3; 4,662.0 / 3,622.3 - 1 = +28.7%; Abbott CGM 7.6 / 5.3 - 1 = +43.4% (2023 to 2025). US share of first half 2026 sales 9,490 / 23,757 = 39.9%. Diagnostics RPO 6,200 / 8,937 = 69% of 2025 Diagnostics sales; 6,200 / 5,360 = 1.16 times Core Laboratory sales. Libre 7.6 / 1.128 = 6.7 times (2018 to 2025). Medical Devices and Established Pharmaceuticals RPO 455 + 243 = 698, / 6,898 = 10.1%. Cash, debt and dividends: free cash flow 9,566 - 2,171 = 7,395 (2025), 8,558 - 2,207 = 6,351 (2024), 7,261 - 2,202 = 5,059 (2023); after dividends 7,395 - 4,116 = 3,279, about $3.3 billion. Dividends paid over free cash flow 4,116 / 7,395 = 55.7%; over net earnings 4,116 / 6,524 = 63.1%; 2025 dividend per share over adjusted EPS 2.40 / 5.15 = 46.6%; annual dividend 4 x 0.63 = 2.52 over trailing EPS 3.09 = 81.6%. Dividend per share 2.40 / 0.98 = 2.45 times, (2.45)^(1/10) - 1 = 9.4% a year (2015 to 2025). Total debt 3,033 + 9,896 = 12,929 (end 2025), 3,005 + 29,603 = 32,608 (30 June 2026); net debt 12,929 - 8,522 - 417 = 3,990 (end 2025), 32,608 - 5,104 - 499 = 27,005 (30 June 2026), 14,679 - 7,279 = 7,400 (end 2023), 14,125 - 7,967 = 6,158 (end 2024); 27,005 / 3,990 = 6.8 times. Remaining performance obligations 6,200 + 455 + 243 = 6,898, about $6.9 billion; Diagnostics share 6,200 / 6,898 = 90%; beyond 36 months 100% - 52% - 18% = 30%; over trailing twelve-month sales 6,898 / 46,585 = 14.8%, about 15%. Trailing twelve months to June 2026: net sales 44,328 - 21,500 + 23,757 = 46,585; net earnings 6,524 - 3,104 + 2,005 = 5,425; diluted EPS 3.72 - 1.77 + 1.14 = 3.09. Expected amortization 1.5bn (2030) / 2.6bn (2026) - 1 = -42%. Analyst target 120.26 / 100.10 - 1 = +20.1%. 2026 adjusted EPS guidance midpoints (5.55 + 5.80) / 2 = 5.675 (January), (5.38 + 5.58) / 2 = 5.48 (April), (5.45 + 5.60) / 2 = 5.525 (July). Year-end market value (stockanalysis) over net earnings and net sales: 2015 66.99bn / 4,423 = 15.15, / 20,405 = 3.283; 2016 56.55 / 1,400 = 40.39, / 20,853 = 2.712; 2017 99.34 / 477 = 208.26, / 27,390 = 3.627; 2018 127.04 / 2,368 = 53.65, / 30,578 = 4.155; 2019 153.61 / 3,687 = 41.66, / 31,904 = 4.815; 2020 194.06 / 4,495 = 43.17, / 34,608 = 5.607; 2021 248.87 / 7,071 = 35.20, / 43,075 = 5.778; 2022 191.43 / 6,933 = 27.61, / 43,653 = 4.385; 2023 191.09 / 5,723 = 33.39, / 40,109 = 4.764; 2024 196.18 / 13,402 = 14.64, / 41,950 = 4.677; 2025 217.86 / 6,524 = 33.39, / 44,328 = 4.915; 5 October 2026 173.21bn / 5,425 = 31.93, / 46,585 = 3.718 - Medical Devices, Diabetes Care and the device lines. — FY2015-Q2 2026 · publ. October 2026 · source ↗
    Method: Arithmetic on figures reported in Abbott Laboratories Forms 10-K and 10-Q and earnings releases, the DexCom Form 10-K, and stockanalysis.com market values; each operand is stated in the source line.
  10. Moat Explorer calcReturn on invested capital was 11.3% in 2025, above an 8% hurdle but well below the 16.5% of 2021.
    Moat Explorer calculation by hand from Abbott Forms 10-K (SEC XBRL operating income, assets, current liabilities and cash concepts are not tagged for Abbott, so tools_roic_edgar.py returns nothing). Return on invested capital 9.6% (2015), 10.0%, 2.8% (2017), 6.2%, 9.0%, 10.8%, 16.5% (2021), 16.1%, 12.5%, 11.6%, 11.3% (2025). Operating earnings 2,867 (2015), 3,185, 1,564 (2017 as recast in the 2019 10-K), 3,650, 4,532, 5,357, 8,425, 8,362, 6,478, 6,825, 8,053 (2025). Tax rates on continuing earnings 18.1% (2015), 24.8%, 35% cap (2017, reported 84.2%), 18.8%, 9.6%, 10.0%, 13.9%, 16.5%, 14.1%, 15% assumed (2024, reported negative after the $7.5 billion valuation allowance release), 22.9% (2025). Invested capital at year end (Abbott shareholders' investment plus short-term borrowings and all long-term debt, less cash and short-term investments): 24,896 (2014), 24,087 (2015), 23,769 (2016), 49,211 (2017), 46,004, 45,087, 44,383, 43,603, 43,289 (2022), 46,003, 53,822, 56,120 (2025: 52,130 + 3,033 + 9,896 - 8,522 - 417). 2025: 8,053 x (1 - 22.9%) = 6,206 / average (53,822 + 56,120) / 2 = 54,971 = 11.3%. At 30 June 2026 goodwill and intangibles were 52,455 against 29,561 at the end of 2025, and net debt 27,005. — FY2015-FY2025 · publ. October 2026 · source ↗
    Method: NOPAT (operating earnings times one minus the effective tax rate on continuing earnings, capped at 35%; 15% assumed for 2024) divided by the average of year-end and prior year-end invested capital (Abbott shareholders' investment plus short-term borrowings, current and long-term debt, less cash and short-term investments), all from Abbott Forms 10-K. 2016 invested capital is depressed by $18.6 billion of cash raised ahead of the St. Jude Medical purchase; 2017 by St. Jude acquisition charges in the recast operating earnings.
  11. ReportedLong-lived assets, mostly property and equipment, were $22.2 billion at the end of 2025 against $18.5 billion a year earlier, and Abbott's 89 manufacturing sites are spread across all four segments.
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - Item 1 business and the segment note: the four segments, sales and operating earnings, employees, manufacturing sites, customers and geography. — FY2025 · publ. 20 February 2026 · source ↗
  12. ReportedLong-lived assets, mostly property and equipment, were $22.2 billion at the end of 2025 against $18.5 billion a year earlier, and Abbott's 89 manufacturing sites are spread across all four segments.
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - Item 1 business and the segment note: the four segments, sales and operating earnings, employees, manufacturing sites, customers and geography. — FY2025 · publ. 20 February 2026 · source ↗
  13. ReportedAbbott paid dividends of $3,556 million in 2023, $3,836 million in 2024 and $4,116 million in 2025, and spent $1,227 million, $1,295 million and $893 million on share purchases.
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - consolidated financial statements: income, taxes, cash flow, dividends, repurchases, debt, goodwill and the critical accounting policy on rebates. — FY2025 · publ. 20 February 2026 · source ↗
Sources
Generated October 6, 2026